144 related articles for article (PubMed ID: 19193109)
1. Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.
Moyle G; DeJesus E; Boffito M; Wong RS; Gibney C; Badel K; MacFarland R; Calandra G; Bridger G; Becker S;
Clin Infect Dis; 2009 Mar; 48(6):798-805. PubMed ID: 19193109
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210.
Johnson VA; Cramer YS; Rosenkranz SL; Becker S; Klingman KL; Kallungal B; Coakley E; Acosta EP; Calandra G; Saag MS;
AIDS Res Hum Retroviruses; 2019 Aug; 35(8):691-697. PubMed ID: 31099252
[TBL] [Abstract][Full Text] [Related]
3. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
Waters L; Mandalia S; Randell P; Wildfire A; Gazzard B; Moyle G
Clin Infect Dis; 2008 May; 46(10):1617-23. PubMed ID: 18419499
[TBL] [Abstract][Full Text] [Related]
4. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.
Mosi RM; Anastassova V; Cox J; Darkes MC; Idzan SR; Labrecque J; Lau G; Nelson KL; Patel K; Santucci Z; Wong RS; Skerlj RT; Bridger GJ; Huskens D; Schols D; Fricker SP
Biochem Pharmacol; 2012 Feb; 83(4):472-9. PubMed ID: 22146583
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1.
Bader J; Däumer M; Schöni-Affolter F; Böni J; Gorgievski-Hrisoho M; Martinetti G; Thielen A; Klimkait T;
Clin Infect Dis; 2017 Feb; 64(3):295-300. PubMed ID: 27838645
[TBL] [Abstract][Full Text] [Related]
6. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
[TBL] [Abstract][Full Text] [Related]
7. CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus.
Ghosn J; Bayan T; Meixenberger K; Tran L; Frange P; d'Arminio Monforte A; Zangerle R; de Mendoza C; Krastinova E; Porter K; Meyer L; Chaix ML;
J Antimicrob Chemother; 2017 Oct; 72(10):2862-2868. PubMed ID: 29091208
[TBL] [Abstract][Full Text] [Related]
8. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
9. Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism.
Soulié C; Charpentier C; Flandre P; Nino C; Carcelain G; Simon A; Katlama C; Landman R; Brun-Vézinet F; Descamps D; Calvez V; Marcelin AG
J Med Virol; 2012 Dec; 84(12):1853-6. PubMed ID: 23080487
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of X4/DM-tropic variants in children and adolescents infected with HIV-1 by vertical transmission.
Briz V; García D; Méndez-Lagares G; Ruiz-Mateos E; de Mulder M; Moreno-Pérez D; Navarro ML; León-Leal JA; de José MI; Ramos JT; Mellado MJ; González-Tomé MI; Leal M; Muñoz-Fernández MA
Pediatr Infect Dis J; 2012 Oct; 31(10):1048-52. PubMed ID: 22828644
[TBL] [Abstract][Full Text] [Related]
12. Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients.
Hernández-Novoa B; Madrid-Elena N; Dronda F; Pérez-Elias MJ; Casado JL; Pérez-Molina JA; Moreno A; Estébanez M; González J; Zamora J; Moreno S
J Antimicrob Chemother; 2014 Jul; 69(7):1916-9. PubMed ID: 24623833
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia.
Spudich SS; Huang W; Nilsson AC; Petropoulos CJ; Liegler TJ; Whitcomb JM; Price RW
J Infect Dis; 2005 Mar; 191(6):890-8. PubMed ID: 15717264
[TBL] [Abstract][Full Text] [Related]
14. Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.
Fransen S; Bridger G; Whitcomb JM; Toma J; Stawiski E; Parkin N; Petropoulos CJ; Huang W
Antimicrob Agents Chemother; 2008 Jul; 52(7):2608-15. PubMed ID: 18443125
[TBL] [Abstract][Full Text] [Related]
15. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.
Schürmann D; Fätkenheuer G; Reynes J; Michelet C; Raffi F; van Lier J; Caceres M; Keung A; Sansone-Parsons A; Dunkle LM; Hoffmann C
AIDS; 2007 Jun; 21(10):1293-9. PubMed ID: 17545705
[TBL] [Abstract][Full Text] [Related]
16. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.
Lalezari J; Thompson M; Kumar P; Piliero P; Davey R; Patterson K; Shachoy-Clark A; Adkison K; Demarest J; Lou Y; Berrey M; Piscitelli S
AIDS; 2005 Sep; 19(14):1443-8. PubMed ID: 16135896
[TBL] [Abstract][Full Text] [Related]
17. Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma.
Soulié C; Tubiana R; Simon A; Lambert-Niclot S; Malet I; Canestri A; Brunet C; Murphy R; Katlama C; Calvez V; Marcelin AG
J Acquir Immune Defic Syndr; 2009 May; 51(1):60-4. PubMed ID: 19390328
[TBL] [Abstract][Full Text] [Related]
18. Existence of Replication-Competent Minor Variants with Different Coreceptor Usage in Plasma from HIV-1-Infected Individuals.
Maeda Y; Takemura T; Chikata T; Kuwata T; Terasawa H; Fujimoto R; Kuse N; Akahoshi T; Murakoshi H; Tran GV; Zhang Y; Pham CH; Pham AHQ; Monde K; Sawa T; Matsushita S; Nguyen TV; Nguyen KV; Hasebe F; Yamashiro T; Takiguchi M
J Virol; 2020 Jun; 94(12):. PubMed ID: 32295903
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance.
de Mendoza C; Rodriguez C; García F; Eiros JM; Ruíz L; Caballero E; Aguilera A; Leiva P; Colomina J; Gutierrez F; del Romero J; Aguero J; Soriano V;
J Antimicrob Chemother; 2007 Apr; 59(4):698-704. PubMed ID: 17327295
[TBL] [Abstract][Full Text] [Related]
20. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
